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Sitagliptin: a potential drug for the treatment of COVID-19?
Recently, an outbreak of a fatal coronavirus, SARS-CoV-2, 
has emerged from China and is rapidly spreading world-
wide. Possible interaction of SARS-CoV-2 with DPP4 pepti-
dase may partly contribute to the viral pathogenesis. An inte-
grative bioinformatics approach starting with mining the 
biomedical literature for high confidence DPP4-protein/gene 
associations followed by functional analysis using network 
analysis and pathway enrichment was adopted. The results 
indicate that the identified DPP4 networks are highly enri-
ched in viral processes required for viral entry and infec-
tion, and as a result, we propose DPP4 as an important puta-
tive target for the treatment of COVID-19. Additionally, our 
protein-chemical interaction networks identified important 
interactions between DPP4 and sitagliptin. We conclude that 
sitagliptin may be beneficial for the treatment of COVID-19 
disease, either as monotherapy or in combination with other 
therapies, especially for diabetic patients and patients with 
pre-existing cardiovascular  conditions who are already at 
higher risk of COVID-19 mortality.
Keywords: SARS-CoV-2, COVID-19, DPP4, ACE2, sitagliptin, 
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In December 2019, an outbreak of fatal coronavirus, COVID-19, has emerged from 
China and is rapidly spreading worldwide due to its high transmission rate (1, 2). This new 
coronavirus is named SARS-CoV-2 which appears to have originated from wild animals 
and birds (2). To date, more than a million cases have been reported globally making 
 COVID-19 a major health issue. Currently, huge efforts are being made towards the develop-
ment of vaccines and antiviral drugs for the treatment of COVID-19.
As the coronavirus pandemic rages, drug discovery and development become even 
more challenging. Research focus has been directed to repurposing already existing, 
 FDA-approved drugs to treat critically ill patients. Drug repurposing is an efficient  approach 
to provide therapeutic moieties with known safety profiles and predicted side -effects for 
the treatment of evolving diseases. In this context, the antimalarial drug chloro quine and its 
hydroxylated form had demonstrated apparent effectiveness in the treatment of COVID-19- 
-associated pneumonia in clinical trials (3, 4). In addition, several other drugs have been 
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reported for their potential efficacy against COVID-19, such as remdesivir, lopin avir, riba-
virin and ritonavir (4, 5).
Lately, the complete genome sequence of SARS-CoV-2 was published and deposited in 
the NCBI database with reference number MN908947.3. The availability of the full genome 
sequence provided a clue for understanding the possible patterns of viral protein glycosy-
lation and proposed mechanisms for viral-host interactions (6). According to the latest 
 published reports, and analogous to most other coronaviruses, the outer membrane spike 
glycoprotein appears to be the key viral protein that interacts with host cellular targets (6, 7).
Interestingly, a model for the homo-trimer structure of COVID-19 spike glycoprotein 
has been published recently (6). According to the study findings, the S1 domain of COVID-19 
spike glycoprotein demonstrates evident interaction with the human CD26, also named 
dipeptidyl peptidase-4 (DPP4), a crucial immunomodulatory protein for hijacking and 
virulence (6).
Remarkably, the SARS-CoV-2 spike protein shares a 31.9 % sequence identity with the 
spike protein present in the Middle East Respiratory Syndrome Corona Virus (MERS-
CoV), another human coronavirus that was first identified in humans in 2012 (8). MERS-
CoV infects cells through the interaction of its spike protein with the DPP4 receptor found 
on macrophages (8). The DPP4 receptor was then identified as one of the most important 
target proteins for antiviral drug development directed against MERS-CoV (8). Indeed, it 
has been demonstrated that the MERS-CoV spike protein activity suppressed macrophage 
responses via DPP4-mediated stimulation of IRAK-M and PPARγ (9), and the observed 
suppression was reversed by the DPP4 inhibitor sitagliptin.
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is known for its antidiabetic, immuno-
regulatory, anti-inflammatory, and beneficial cardiometabolic effects (10, 11). Interestingly, 
sitagliptin diminished hepatitis C virus replication in a diabetic patient by an unknown 
mechanism (12). In addition, sitagliptin was shown to suppress the production of inter-
feron gamma-induced protein 10 (CXCL10) chemokine in AIDS patients (13). Very recently, 
CXCL10 chemokine has been detected at a high level of expression in the lung broncho-
alveolar microenvironment of COVID-19 patients (14).
In the view of the current public health catastrophe and considering the potential 
molecular interactions between COVID-19 spike protein and DPP4, we suggest that DPP4 
inhibition may be potentially useful as an alternative for the treatment of COVID-19 dis-
ease especially in diabetic patients and patients with pre-existing cardiovascular condi-
tions who are already at higher risk of COVID-19 mortality.
METHODS
Database mining to identify DPP4 functional partners
A systematic search for human DPP4’s nearest neighbor (NN) proteins was conducted 
in Cytoscape (15) version 3.7.2 using the STRING (16) protein query application. All retrie-
ved protein-protein interactions, including both physical and functional interactions were 
retrieved from popular databases such as MINT (17), HPRD (18), BIND (19), DIP (20), 
 BioGRID (21), KEGG (22), Reactome (23), EcoCyc (24), NCI-Nature Pathway Interaction 
 Database (25), and Gene Ontology (GO) (26) protein complexes.
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Network building
Network building tools in Cytoscapes version 3.7.2 were used to generate DPP4-pro-
tein interaction networks.
Pathway enrichment analysis
Functional enrichment tools in Cytoscape were applied to conduct an over-represen-
tation analysis of DPP4 and its NN proteins in biological pathways to determine whether 
DPP4’s NN protein network is important in viral and immune processes.
Protein structure analysis
The crystal structure of DPP-IV (PDB ID: 1X70) (27) co-crystallized with sitagliptin 
(715) was retrieved from the RCSB Protein Data Bank (28).
RESULTS AND DISCUSSION
Viruses require receptors on the surface of the target cell to launch infection. There 
has been a huge focus in the reported literature on the ability of both SARS-CoV-2 and 
SARS-CoV to bind to angiotensin-converting enzyme II (ACE2) protein in order to invade 
the host cells (29, 30). Since the outbreak, many studies were published reporting the dis-
Fig. 1. DPP4 nearest neighbor proteins. The nodes are color-coded using a split pie chart coloring 
scheme indicating enriched GO terms involved in viral, inflammatory and immune processes. All 
details about the complete list of enriched pathways, network genes, gene sets, background genes 
and enrichments are found in Supplementary Table S1.
178
S. K. Bardaweel et al.: Sitagliptin: a potential drug for the treatment of COVID-19?, Acta Pharm. 71 (2021) 175–184.
 
tribution of ACE2 receptor in the different types of human cells, such as lung, liver, kidney, 
and colon (31) and suggesting that SARS-CoV-2 may infect different organs in the human 
body. Nevertheless, the main target cell for SARS-CoV-2 entry, lung alveolar type 2 (AT2) 
cells, were shown to express rather low levels of ACE2 (31) suggesting a possible existence 
of co-membrane proteins facilitating host entry and infection.
Our results showed that DPP4 interacts with several proteins that are important for 
viral processes and immune responses including ACE2, which implies a cross-talk  between 
the two proteins that warrants additional investigation. We identified supporting evidence 
from the biomedical literature in two recent reports which highlighted the possible role of 
DPP4 as an alternative pathway for SARS-CoV-2 entry and infection (6, 32). Indeed, DPP4 
has been suggested as a candidate co-receptor for SARS-CoV-2 entry, displaying analogous 
expression patterns with ACE2 across 13 human tissues (32).
A network of DPP4’s functional NN proteins was generated using the STRING protein 
interaction app in Cytoscape as illustrated in Fig. 1. In this network, nodes are identified 
as NN proteins and edges are indicating the type of evidence for the mined protein-protein 
interactions. The network generating algorithm included interactions from text and database 
mining, direct experiments, co-expression, and co-occurrence.
Additionally, DPP4 and its NN proteins were used as a query for an automated over-
representation analysis conducted across all annotated biological pathways included in 
STRING. This analysis highlighted enriched GO processes and GO functions associated 
with viral, inflammatory and immune processes. The most important enriched terms with 
false discovery rates (FDRs) lower than 0.05 were: “virus receptor activity”, “viral entry 
into host cell”, “T-cell receptor”, “positive regulation of T cell activation”, and “acute 
 inflammatory response”.
Interestingly, supporting the idea that DPP4 inhibition may be beneficial as a treat-
ment option for COVID-19, recent studies have demonstrated that DPP4 inhibitors interact 
Fig. 2. Crystal structure of dipeptidyl peptidase IV (DPP4, DPP-IV) (PDB ID: 1X70) (27) in complex 
with sitagliptin (715). The picture is created by NGL (28, 34).
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with ACE2 at a relatively reasonable binding energy (33). Moreover, in vivo studies showed 
that sitagliptin could inhibit ACE activity and reduce angiotensin II levels in rats (33).
In order to identify the structural basis of the binding of sitagliptin in DPP4, we 
 adopted the crystal structure of DPP4 (PDB ID: 1X70) co-crystallized with sitagliptin (715) 
Fig. 2 (27).
The hydrophilic and hydrophobic residues occupy DPP4 binding cleft. The binding 
pocket of DPP4 encloses E205, E206, V207, F208, S209, F357, R358, Y547, S630, Y631, V656, 
W659, Y662, D663, Y666, and H740. Interestingly, the hydrophilic and hydrophobic exposed 
surfaces of sitagliptin agree with the nearby residues. The aromatic residues furnish aro-
matic (π-π stacking) whereas hydrophobic amino acids mediate hydrophobic interaction. 
On the contrary, the hydrophilic residues provide dipole-dipole, hydrogen-bonding, and 
ion-dipole interactions. And the acidic and basic residues offer an electrostatic (ionic) bond.
Furthermore, to investigate the functional effects resulting from DPP4 inhibition by 
sitagliptin, we built a new network for DPP4 using all reported protein targets for sita-
gliptin as seeds, which included DPP4, CYP2C8, FASLG, HMGCR and SLC22A8. The 
 resulting network, which consisted of all of the above-mentioned sitagliptin’s protein targets 
seed nodes, was then expanded with the addition of 20 first-shell protein interactions, and 
20-second shell protein interactions. All proteins in the extended network were then used 
for the enrichment analysis in STRING. Results for pathways involving viral processes are 
shown in Table I and all details about the complete list of enriched pathways, network 
genes, gene sets, background genes and enrichments are found in supplementary Table S2.
Our extended network highlighted an important role of caveolin-1 (CAV1) in sita-
gliptin’s functional interactions (Fig. 3). In fact, caveolin-1 may act as a scaffolding protein 
within caveolar membranes; it interacts directly with G-protein alpha subunits and can 
functionally regulate their activity. It is also involved in the co-stimulatory signal essential 
for the T-cell receptor (TCR)-mediated T-cell activation. Binding of CAV1 to DPP4 induces 
T-cell proliferation and NF-kappa-B activation in a T-cell receptor CD3-dependent manner 
(35). Noteworthy, the endocytic pathway and the autophagy process are key elements in 
viral infection and have gained considerable attention over the last years. Hence, the 







Viral mRNA translation Reactome pathway 18 86 2.88E-26
Viral process GO process 11 571 5.15E-06
Viral life cycle GO process 7 166 6.40E-06
ISG15 antiviral mechanism Reactome pathway 3 69 0.0016
Viral entry into the host cell GO process 3 92 0.0091
Viral myocarditis KEGG pathway 2 56 0.0369
Host-virus interaction Keywords 5 432 0.0386
FDR – false discovery rate
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 endocytic pathway, embracing endosome and lysosome, was often suggested as a hot  target 
for the development of new therapeutic approaches in tackling coronaviruses’ infections 
(35). Nevertheless, and despite the general agreement on the endocytic pathway role in 
viral entry, there are several contradicting reports with major discrepancies in the precise 
mechanism via which this pathway mediates SARS-CoV infections (35).
For example, Wang et al. (36) reported that SARS-CoVs use clathrin- and caveolae- 
- independent endocytic pathway as the main mechanism for viral entry, whereas other 
studies demonstrate that SARS-CoV cell entry is chiefly facilitated by the clathrin-depen-
dent pathway (37).
Currently, the precise mechanism of cell entry and the involvement of the endocytic 
pathway of the new evolving SARS-CoV-2 have not been described thoroughly. However, 
Fig. 3. Expanded protein interactions network of sitagliptin’s drug targets. The nodes were clustered 
using K-means clustering setting the number of clusters to 5 and colored as red, green, violet, cyan 
and yellow. Edges are colored according to their action types explained in the figure. 
181
S. K. Bardaweel et al.: Sitagliptin: a potential drug for the treatment of COVID-19?, Acta Pharm. 71 (2021) 175–184.
 
there is growing evidence supporting that SARS-CoV-2 utilizes the same entry receptor 
that SARS-CoV uses, the ACE2 membrane protein (29, 30). In addition, it has been reported 
that SARS-CoV-2 is sensitive to the inhibitory effects of the antimalarial drug chloroquine, 
a compound with lysosomotropic properties. Therefore, it is likely that the emerging 
SARS-CoV-2 utilizes more than one pathway for cell entry such as the endocytic pathway 
used by other SARS-CoVs and the ACE2 receptor entry mechanism, both of which may 
cross-talk with the multifunctional DPP4 protein.
Interestingly, a similar case scenario has been reported with the human immunodefi-
ciency virus (HIV) where the CD4 antigen is shown to be essential for the binding of the 
virus but is not enough for efficient viral entry and infection (38). Later, the CD26/DPP4 has 
been demonstrated as a crucial cofactor for efficient viral entry and the co-expression of 
human CD4 and CD26/DPP4 in murine NIH 3T3 cells resulted in evident infection by HIV 
(38). It could be that emerging SARS-CoV-2 utilizes similar patterns of ACE2/DPP4 cross-
talk and that specific inhibitors that block the function of DPP4 may be effective therapeutic 
agents in COVID-19. Further investigation into the inhibitory effects of sitagliptin on viral 
entry and infection should shed light on possible therapeutic avenues for the treatment of 
COVID-19.
CONCLUSIONS
Taken together, we conclude that the use of DPP4 inhibitors such as sitagliptin may be 
a potential treatment of COVID-19 disease, either as monotherapy or in the combination 
with other therapies, especially for diabetic patients and patients with pre-existing cardio-
vascular conditions who are already at higher risk of COVID-19 mortality.
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